Reviva Pharmaceuticals Holdings (RVPH) AI Stock Analysis

• Market Cap: $37.06M
• Dividend Yield: N/A
• Average Volume (3M): 529.97K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.47
• Revenue Growth: N/A
• EPS Growth: 45.15%
• Country: US
• Employees: 14
• Sector: Healthcare
• Sector Strength: 55
• Industry: Biotechnology
• EPS (TTM): -0.13
• Shares Outstanding: 46,739,950
• 10 Day Avg. Volume: 763,404
• 30 Day Avg. Volume: 529,974
• PEG Ratio: -0.03
• Price to Book (P/B): 6.73
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.37
• Enterprise Value/Market Cap: 1.74
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.53
• 1Y Price Target: $9.00
• Price Target Upside: 1053.85% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 28 Underperform
• Price Target: ―

Reviva Pharmaceuticals Holdings faces significant financial challenges, with zero revenue, substantial net losses, and negative cash flows, heavily weighing down its stock score. The technical analysis indicates weak momentum and a downward trend, while the negative P/E ratio and lack of dividends reflect poor valuation. Recent corporate events show leadership confidence but do not mitigate the underlying financial distress.

Positive Factors

Competitive Edge

Recent setbacks for drugs targeting the muscarinic system as an alternative to the current selection of atypical antipsychotics have left Brilaroxazine as one of the few viable Phase 3 assets in the space.

Efficacy and Safety

The long-term safety profile remained positive as well, with a 35% discontinuation rate that compares favorably to the 60%-70% typically seen in similar-duration trials of other antipsychotics.

Therapeutic Potential

Brilaroxazine demonstrated sustained, dose-dependent efficacy across all key symptom domains (positive, negative, cognitive, agitation), underscoring its therapeutic potential in treating schizophrenia.

Negative Factors

Capital Requirement

The company will need to raise additional capital to support its upcoming P3 study, which we factor into our model.

Financial Needs

The company, who ended the quarter with $13.5 million in cash, will likely need additional capital in order to move its clinical programs forward.

Funding Challenges

The company will likely need additional capital in order to move its clinical programs forward.

Reviva Pharmaceuticals Holdings Business Overview & Revenue Model

Company Description

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.

How the Company Makes Money

Reviva Pharmaceuticals Holdings generates revenue primarily through the development and commercialization of its drug candidates. The company relies on funding from partnerships, collaborations, and potential licensing agreements with larger pharmaceutical companies. These partnerships may include milestone payments and royalties based on the successful development and commercialization of its products. Additionally, Reviva may receive grants or research funding from governmental or non-governmental organizations to support its drug development programs. As a clinical-stage company, its revenue generation is heavily dependent on the successful advancement of its pipeline through clinical trials and achieving regulatory approvals.

Reviva Pharmaceuticals Holdings Financial Statement Overview

Summary

Reviva Pharmaceuticals Holdings is in a precarious financial position, characterized by zero revenue, substantial net losses, and negative cash flows. The balance sheet reflects weak financial health with low equity and high liabilities, posing significant risks. Overall, the company faces serious financial challenges with no immediate sign of improvement in revenue generation or profitability.

Income Statement

Reviva Pharmaceuticals Holdings has consistently reported zero revenue, which is a significant concern for profitability and growth potential. The company has experienced substantial net losses over the years, indicating financial instability. The EBIT and EBITDA margins are negative, reflecting operating inefficiencies and a lack of financial viability.

Balance Sheet

The company's balance sheet reveals a high degree of financial distress, with a very low stockholders' equity and high liabilities relative to assets. The negative equity in previous years indicates severe financial challenges. Although debt levels are currently low, the overall financial position remains weak with significant risks.

Cash Flow

Cash flow analysis shows persistent negative free cash flow, highlighting liquidity concerns and the inability to generate cash from operations. The operating cash flow to net income ratio is unfavorable, indicating poor cash generation relative to reported net losses. Despite some financing inflows, overall cash flow health is poor.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	0.00	0.00	0.00	-724.74K
	EBIT
-30.80M	-39.50M	-24.31M	-10.10M	-2.43M
	EBITDA
-29.88M	-39.50M	-24.11M	-10.10M	-2.33M
	Net Income Common Stockholders
-29.92M	-39.26M	-24.34M	-8.52M	-3.78M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
13.48M	23.37M	18.52M	29.69M	8.76M
	Total Assets
15.50M	23.70M	18.92M	31.40M	8.76M
	Total Debt
458.15K	0.00	0.00	0.00	0.00
	Net Debt
-13.02M	-23.37M	-18.52M	-29.69M	-8.76M
	Total Liabilities
14.69M	17.98M	6.61M	2.72M	1.33M
	Stockholders Equity
812.57K	5.72M	12.32M	28.69M	7.43M
Cash Flow		Free Cash Flow
-33.54M	-28.32M	-18.96M	-10.67M	-3.73M
	Operating Cash Flow
-33.54M	-28.32M	-18.96M	-10.67M	-3.73M
	Investing Cash Flow
0.00	0.00	0.00	0.00	0.00
	Financing Cash Flow
23.65M	33.17M	7.79M	31.60M	12.83M

Reviva Pharmaceuticals Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.78
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RVPH, the sentiment is Negative. The current price of 0.78 is below the 20-day moving average (MA) of 0.91, below the 50-day MA of 0.81, and below the 200-day MA of 1.28, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 42.22 is Neutral, neither overbought nor oversold. The STOCH value of 8.19 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RVPH.

Reviva Pharmaceuticals Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.38B	3.31	-45.11%	3.29%	16.82%	0.04%
CNTB	49 Neutral	$45.33M	―	-58.89%	―	―	―
DYAI	46 Neutral	$29.79M	―	-214.26%	―	20.58%	15.90%
PEPG	40 Underperform	$49.08M	―	-75.45%	―	―	14.06%
OKYO	38 Underperform	$78.96M	―	0.00%	―	―	―
RVPH	28 Underperform	$37.06M	―	-916.17%	―	―	45.15%
CAMP		$33.27M	―		―	―	―

Reviva Pharmaceuticals Holdings Corporate Events

Reviva Pharmaceuticals Approves Executive Compensation Changes

On February 13, 2025, Reviva Pharmaceuticals Holdings’ Compensation Committee approved several compensation arrangements for its executives, with retroactive base salary increases effective from January 1, 2025. Additionally, the committee set new bonus targets for 2025 and approved significant stock option grants, reflecting confidence in the leadership team and aligning their interests with shareholders.